Investing.com -- Formycon has launched FYB201/Ranivisio as the first ranibizumab biosimilar available in a pre-filled syringe format in Europe, starting in France in October 2025.

The Swiss cable and connectivity group maintained its 2025 guidance, expecting full-year sales to match 2024 levels and an EBIT margin within its medium-term target range of 9–12%, assuming no major ...

Investing.com - European stocks steadied Monday, mostly retaining the positive tone seen at the start of the week as ...

Investing.com-- The U.S. Army has approached leading private equity firms including Apollo, Carlyle (NASDAQ:CG), KKR (NYSE:KKR) and Cerberus for proposals to help fund a $150 billion infrastructure ...